title: Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib.
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Siraj M
authors.initials: SM
authors.lastname: Ali
authors.affiliation: Department of Pathology.
authors.forename: R Kathy
authors.initials: RK
authors.lastname: Alpaugh
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Jamie K
authors.initials: JK
authors.lastname: Buell
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Stephens
authors.affiliation: Department of Diagnostic Imaging, Fox Chase Cancer Center, Philadelphia, PA.
authors.forename: Jian Qin Michael
authors.initials: JQ
authors.lastname: Yu
authors.affiliation: Department of Pathology.
authors.forename: Hong
authors.initials: H
authors.lastname: Wu
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Christine N
authors.initials: CN
authors.lastname: Hiemstra
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Vincent A
authors.initials: VA
authors.lastname: Miller
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Doron
authors.initials: D
authors.lastname: Lipson
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA.
authors.forename: Gary A
authors.initials: GA
authors.lastname: Palmer
authors.affiliation: Foundation Medicine, Inc, Cambridge, MA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY.
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Ross
authors.affiliation: Department of Pathology. Electronic address: Massimo.Cristofanilli@Jefferson.edu.
authors.forename: Massimo
authors.initials: M
authors.lastname: Cristofanilli
mesh_terms: D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005260:Female; D006801:Humans; D058922:Inflammatory Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009154:Mutation; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors
keywords: HER2; Inflammatory breast cancer; Lapatinib; Next-generation sequencing; Trastuzumab